Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 73

1.

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.

Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE.

Breast Cancer Res. 2015 Apr 16;17(1):56. [Epub ahead of print]

PMID:
25888246
2.

Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study.

Vaz-Luis I, Hughes ME, Cronin AM, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU.

Cancer. 2015 Mar 10. doi: 10.1002/cncr.29310. [Epub ahead of print]

PMID:
25757412
3.

Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.

Boyle FM, Smith IE, O'Shaughnessy J, Ejlertsen B, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Amonkar M, Huang Y, Rappold E, Williams LS, Wang-Silvanto J, Kaneko T, Finkelstein DM, Goss PE; TEACH investigators.

Eur J Cancer. 2015 Apr;51(6):685-96. doi: 10.1016/j.ejca.2015.02.005. Epub 2015 Mar 6.

PMID:
25752740
4.

Case records of the Massachusetts General Hospital. Case 1-2015. A 66-year-old woman with metastatic breast cancer after endocrine therapy.

Moy B, Specht MC, Lanuti M, Rafferty EA, Lerwill MF.

N Engl J Med. 2015 Jan 8;372(2):162-70. doi: 10.1056/NEJMcpc1408601. No abstract available.

PMID:
25564900
5.

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP.

N Engl J Med. 2015 Jan 8;372(2):134-41. doi: 10.1056/NEJMoa1406281.

6.

Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience.

Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE.

J Clin Oncol. 2015 Feb 1;33(4):340-8. doi: 10.1200/JCO.2013.54.6119. Epub 2014 Dec 22.

PMID:
25534386
7.

American Society of Clinical Oncology policy statement on medicaid reform.

Polite BN, Griggs JJ, Moy B, Lathan C, duPont NC, Villani G, Wong SL, Halpern MT.

J Clin Oncol. 2014 Dec 20;32(36):4162-7. doi: 10.1200/JCO.2014.56.3452. Epub 2014 Nov 17. No abstract available.

PMID:
25403206
8.

Debating the oncologist's role in defining the value of cancer care: our duty is to our patients.

Sulmasy D, Moy B.

J Clin Oncol. 2014 Dec 20;32(36):4039-41. doi: 10.1200/JCO.2014.57.8716. Epub 2014 Nov 3. No abstract available.

PMID:
25366686
9.

Gene deletions in Mycobacterium bovis BCG stimulate increased CD8+ T cell responses.

Panas MW, Sixsmith JD, White K, Korioth-Schmitz B, Shields ST, Moy BT, Lee S, Schmitz JE, Jacobs WR Jr, Porcelli SA, Haynes BF, Letvin NL, Gillard GO.

Infect Immun. 2014 Dec;82(12):5317-26. doi: 10.1128/IAI.02100-14. Epub 2014 Oct 6.

PMID:
25287928
10.

Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D, Brundage SB, Danso MA, Wilcox M, Smith IE.

J Clin Oncol. 2014 Oct 10;32(29):3307-29. doi: 10.1200/JCO.2014.56.7479. Epub 2014 Sep 2.

PMID:
25185096
11.

Measuring decision quality: psychometric evaluation of a new instrument for breast cancer chemotherapy.

Lee CN, Wetschler MH, Chang Y, Belkora JK, Moy B, Partridge A, Sepucha KR.

BMC Med Inform Decis Mak. 2014 Aug 20;14:73. doi: 10.1186/1472-6947-14-73.

12.

Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.

Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU.

J Clin Oncol. 2014 Jul 10;32(20):2142-50. doi: 10.1200/JCO.2013.53.1608. Epub 2014 Jun 2.

PMID:
24888816
13.

Value of cancer care: ethical considerations for the practicing oncologist.

Jagsi R, Sulmasy DP, Moy B.

Am Soc Clin Oncol Educ Book. 2014:e146-9. doi: 10.14694/EdBook_AM.2014.34.e146.

14.

Geriatric oncology for the 21st century: a call for action.

Moy B, Flaig TW, Muss HB, Clark B, Tse W, Windham TC.

J Oncol Pract. 2014 Jul;10(4):241-3. doi: 10.1200/JOP.2013.001333. Epub 2014 Apr 29. No abstract available.

15.

Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I.

Oncologist. 2014 Apr;19(4):348-9. doi: 10.1634/theoncologist.2014-0021. Epub 2014 Mar 27.

16.

Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I.

Oncologist. 2014 Apr;19(4):346-7. doi: 10.1634/theoncologist.2014-0022. Epub 2014 Mar 27.

17.

Massachusetts general hospital: improving patient access to the breast oncology clinic.

Lennes IT, Bloom M, Bohlen N, Moy B.

J Natl Compr Canc Netw. 2014 Feb;12 Suppl 1:S25-7.

PMID:
24614048
18.

Ethical considerations for the clinical oncologist in an era of oncology drug shortages.

Jagsi R, Spence R, Rathmell WK, Bradbury A, Peppercorn J, Grubbs S, Moy B.

Oncologist. 2014 Feb;19(2):186-92. doi: 10.1634/theoncologist.2013-0301. Epub 2014 Jan 21.

19.

Hemodynamic signature of breast cancer under fractional mammographic compression using a dynamic diffuse optical tomography system.

Carp SA, Sajjadi AY, Wanyo CM, Fang Q, Specht MC, Schapira L, Moy B, Bardia A, Boas DA, Isakoff SJ.

Biomed Opt Express. 2013 Nov 22;4(12):2911-24. doi: 10.1364/BOE.4.002911. eCollection 2013.

20.

A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.

Lin NU, Freedman RA, Ramakrishna N, Younger J, Storniolo AM, Bellon JR, Come SE, Gelman RS, Harris GJ, Henderson MA, Macdonald SM, Mahadevan A, Eisenberg E, Ligibel JA, Mayer EL, Moy B, Eichler AF, Winer EP.

Breast Cancer Res Treat. 2013 Nov;142(2):405-14. doi: 10.1007/s10549-013-2754-0. Epub 2013 Nov 7.

PMID:
24197661
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk